Daily Stock Analysis, MESO, Mesoblast Ltd, priceseries

Mesoblast Ltd. Daily Stock Analysis
Stock Information
Open
3.68
Close
3.58
High
3.68
Low
3.55
Previous Close
3.77
Daily Price Gain
-0.19
YTD High
5.09
YTD High Date
Jan 4, 2022
YTD Low
3.55
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.40
YTD Gain
-28.11%
52 Week High
9.87
52 Week High Date
Mar 16, 2021
52 Week Low
3.55
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-5.14
52 Week Gain
-58.94%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
5.49
Jan 20. 2017
5.83
10 Trading Days
6.29%
Link
LONG
Feb 10. 2017
5.83
Feb 27. 2017
6.13
10 Trading Days
5.07%
Link
LONG
Mar 16. 2017
7.95
Mar 31. 2017
8.57
11 Trading Days
7.79%
Link
LONG
Dec 6. 2017
5.14
Jan 3. 2018
5.80
18 Trading Days
12.75%
Link
LONG
Feb 20. 2018
5.27
Mar 8. 2018
7.11
12 Trading Days
34.92%
Link
LONG
Jul 16. 2018
6.00
Jul 25. 2018
6.41
7 Trading Days
6.91%
Link
LONG
Sep 17. 2018
6.11
Oct 2. 2018
7.42
11 Trading Days
21.40%
Link
LONG
Dec 28. 2018
3.95
Jan 22. 2019
4.70
15 Trading Days
18.88%
Link
LONG
Sep 10. 2019
6.08
Sep 24. 2019
6.72
10 Trading Days
10.60%
Link
LONG
Dec 4. 2019
6.27
Dec 18. 2019
6.76
10 Trading Days
7.82%
Link
LONG
Dec 23. 2019
7.03
Jan 31. 2020
9.70
26 Trading Days
37.91%
Link
LONG
May 4. 2020
10.71
Jun 5. 2020
12.86
21 Trading Days
20.06%
Link
LONG
Jun 8. 2021
7.61
Jun 25. 2021
8.16
13 Trading Days
7.17%
Link
Company Information
Stock Symbol
MESO
Exchange
NasdaqGS
Company URL
http://www.mesoblast.com
Company Phone
-
CEO
Silviu Itescu
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Description

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopedic disorders, and oncologic/hematologic conditions. The company's lead product candidates include MPC-150-IM, a Phase 3 product candidate under investigation for the treatment of chronic congestive heart failure; MPC-06-ID, a Phase 3 product candidate under investigation for the treatment of chronic low back pain due to disc degeneration; MSC-100-IV, a Phase 3 intravenously-delivered product candidate, which is developed for the treatment of acute graft versus host disease following allogeneic bone marrow transplantation; and MPC-300-IV, an intravenously-delivered immunomodulatory product candidate for the treatment of chronic inflammatory conditions, including biologic-refractory rheumatoid arthritis, and diabetic nephropathy, which is under Phase 2 trial. It has a collaboration agreement with JCR Pharmaceuticals Co., Ltd to offer TEMCELL HS. Inj., a product based on its proprietary mesenchymal lineage adult stem cell technology for the treatment of graft versus host disease. The company has operations in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was founded in 2004 and is based in Melbourne, Australia.